Mkt Cap$2.30T-0.85%
24h Vol$66.51B
BTC Dom56.3%
ETH Dom9.9%
F&G25Extreme Fear
BTC$64,354.00-0.93% ETH$1,875.11-2.02% USDT$0.9993+0.02% BNB$576.74-0.16% USDC$0.9999+0.00% XRP$1.11-0.37% SOL$76.11-1.64% TRX$0.3231-0.31% FIGR_HELOC$1.04-0.04% HYPE$64.20-4.62% DOGE$0.0733-0.39% USDS$0.9998+0.00% ZEC$553.68-3.33% RAIN$0.0139-3.98% LEO$9.83+0.14% WBT$56.26-1.04% BTC$64,354.00-0.93% ETH$1,875.11-2.02% USDT$0.9993+0.02% BNB$576.74-0.16% USDC$0.9999+0.00% XRP$1.11-0.37% SOL$76.11-1.64% TRX$0.3231-0.31% FIGR_HELOC$1.04-0.04% HYPE$64.20-4.62% DOGE$0.0733-0.39% USDS$0.9998+0.00% ZEC$553.68-3.33% RAIN$0.0139-3.98% LEO$9.83+0.14% WBT$56.26-1.04%
News

Earnings

Total Stories
1,193
Section
Earnings
Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts
Earnings

Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts

Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year.

Tim FriesJul 18, 20243 min read